Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma

Journal of Gastrointestinal Cancer

Volumn 41, Issue 2, 2010, Pages 149-152

  Welker, Martin Walter ^a   Zangos, Stephan ^a   Kriener, Susanne ^b   Mönch, Christian ^b   Zeuzem, Stefan ^b   Trojan, Joerg ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Hepatocellular carcinoma; Sorafenib; TACE

Indexed keywords

DOXORUBICIN; SORAFENIB; ANTINEOPLASTIC AGENT; BENZENESULFONIC ACID DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ADULT; ARTICLE; CANCER STAGING; CASE REPORT; CHEMOEMBOLIZATION; DIARRHEA; FATIGUE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN MANIFESTATION; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLISATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE-FREE SURVIVAL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PYRIDINES; NIACINAMIDE; PHENYLUREA COMPOUNDS;

EID: 77954621344     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-010-9146-z     Document Type: Article

References (14)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907-17.
2. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
3. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-42.
4. Vogl TJ, Naguib NN, Nour-Eldin NE, Rao P, Emami AH, Zangos S, et al. Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol. 2009;72:505-16.
5. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90.
6. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A, et al. Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol. 2008;103:914-21.
7. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
8. Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol. 2001;13:291-4.
9. Furuse J. Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol. 2008;67:8-15.
10. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878-82.
11. Song BC, Chung YH, Kim JA, Lee HC, Yoon HK, Sung KB, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study. Cancer. 2001;91:2386-93.
12. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology. 2008;75 Suppl 1:1-12.
13. Hoffmann K, Glimm H, Radeleff B, Richter G, Heining C, Schenkel I, et al. Prospective, randomized, double-blind, multicenter, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008;8:349.
14. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev Anticancer Ther. 2008;8:1743-49.